Apogee Therapeutics (APGE) stock was up 18% pre-bell Monday after the company said that 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and "deepening" response for lesional and itch endpoints.
Indivior (INDV) shares were 13% higher following a 3.9% loss in the previous session.
Synopsys (SNPS) stock was up 4.2% after media reports over the weekend that Elliott Investment Management has built a multibillion-dollar stake in the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments